AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35979021 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable nitride iron stents (IBS)
Number of subjects: 11
Study 35979039 — intervention group
Group type: COMPARATOR
Intervention: Elevated PTSD symptoms
Number of subjects: 635
Study 35979039 — intervention group
Group type: COMPARATOR
Intervention: Alcohol or cannabis comorbidity
Number of subjects: 635
Study 35979039 — intervention group
Group type: COMPARATOR
Intervention: Stimulant comorbidity
Number of subjects: 635
Study 35979039 — intervention group
Group type: COMPARATOR
Intervention: Opioid comorbidity
Number of subjects: 635
Study 35979886 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytical treatment interruption (ATI) during the HIV cure-directed trial
Number of subjects: 15
Study 35979886 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivations for trial participation
Number of subjects: 15
Study 35979886 — intervention group
Group type: EXPERIMENTAL
Intervention: Support systems for trial enrollment decision
Number of subjects: 15
Study 35979886 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of trial procedures
Number of subjects: 15
Study 35979886 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns regarding ATI
Number of subjects: 15
Study 35979886 — intervention group
Group type: EXPERIMENTAL
Intervention: Excitement for trial participation
Number of subjects: 15
Study 35980235 — intervention group
Group type: EXPERIMENTAL
Intervention: osilodrostat (starting dose 2 mg bid; maximum 30 mg bid)
Number of subjects: 137
Study 35980235 — intervention group
Group type: EXPERIMENTAL
Intervention: osilodrostat
Number of subjects: 137
Study 35980739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumme Quit Smoking app and smartwatch combination
Number of subjects: 40
Study 35980739 — intervention group
Group type: COMPARATOR
Intervention: Control arm with 8-week supply of nicotine replacement therapy, 30-minute smoking cessation counseling session, and weekly check-in calls
Number of subjects: 40
Study 35980739 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms together (intervention and control)
Number of subjects: 40
Study 35981452 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 52
Study 35981626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortnightly questionnaires assessing anxiety, depression, and stress
Number of subjects: 211
Study 35981626 — intervention group
Group type: COMPARATOR
Intervention: Reassignment of healthcare workers
Number of subjects: 211
Study 35981784 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin carotenoid score (SCS) measurement using reflection spectroscopy (RS)
Number of subjects: 21
Study 35981784 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin carotenoid score (SCS) measurement using reflection spectroscopy (RS) in 8-month-olds
Number of subjects: 21
Study 35981784 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin carotenoid score (SCS) measurement using reflection spectroscopy (RS) in 6-month-olds
Number of subjects: 21
Study 35981916 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualized fibroid at any time during pregnancy
Number of subjects: 2774
Study 35981916 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fibroid volume change
Number of subjects: 2774
Study 35981916 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fibroid volume change for small volume
Number of subjects: 2774
Study 35981916 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fibroid volume change for medium volume
Number of subjects: 2774
Study 35981916 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fibroid volume change for large volume
Number of subjects: 2774
Study 35981916 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualized fibroid number change
Number of subjects: 2774
Study 35981916 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fibroid volume change by race/ethnicity
Number of subjects: 2774
Study 35981917 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal arteriolar caliber and retinal venular curvature tortuosity
Number of subjects: 456
Study 35981917 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal curvature tortuosity (per SD increase)
Number of subjects: 456
Study 35982228 — intervention group
Group type: EXPERIMENTAL
Intervention: Good pain control under analgesic treatment
Number of subjects: 80
Study 35982228 — intervention group
Group type: EXPERIMENTAL
Intervention: No or minor pain
Number of subjects: 80
Study 35982228 — intervention group
Group type: COMPARATOR
Intervention: Poor pain control despite analgesic treatment
Number of subjects: 80
Study 35982244 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal voice exposure (twice daily for 20 minutes before oral feeding)
Number of subjects: 25
Study 35982396 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity of the right and left antero-dorsal insula in MA patients.
Number of subjects: 21
Study 35982396 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional connectivity analysis using seed-to-voxel analysis in MA patients.
Number of subjects: 21
Study 35982396 — intervention group
Group type: COMPARATOR
Intervention: Comparison of functional connectivity in MA patients versus MO patients.
Number of subjects: 21
Study 35982403 — intervention group
Group type: EXPERIMENTAL
Intervention: Carina-distal (C-D) group
Number of subjects: 168
Study 35982403 — intervention group
Group type: COMPARATOR
Intervention: Carina-proximal (C-P) group
Number of subjects: 168
Study 35982403 — intervention group
Group type: COMPARATOR
Intervention: Carina-carina (C-C) group
Number of subjects: 168
Study 35982410 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher preoperative serum PGE2 levels
Number of subjects: 131
Study 35982410 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher preoperative serum neurofilament light levels
Number of subjects: 131
Study 35982410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower preoperative MMSE scores
Number of subjects: 131
Study 35982410 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 131
Study 35982424 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher rates of depression
Number of subjects: 316
Study 35982424 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative attitudes to aging
Number of subjects: 316
Study 35982424 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 316
Study 35982424 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual impairment (in men)
Number of subjects: 316
Study 35982424 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowered self-sufficiency in ADL (in women)
Number of subjects: 316
Study 35982495 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TMAO (tertiles)
Number of subjects: 2088
Study 35982495 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of serum TMAO
Number of subjects: 2088
Study 35982495 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TMAO
Number of subjects: 2088
Study 35982649 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate 200 μg once daily for 14 days
Number of subjects: 1277
Study 35982649 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate
Number of subjects: 1277
Study 35982649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1277
Study 35982649 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 1277
Study 35982669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 400 µg/kg daily for 3 days
Number of subjects: 1591
Study 35982669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1591
Study 35982675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study 35982675 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 35983024 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (250 mg once daily) combined with docetaxel (IV every 3 weeks for four cycles) followed by epirubicin plus cyclophosphamide (IV every 3 weeks for four cycles)
Number of subjects: 31
Study 35983025 — intervention group
Group type: EXPERIMENTAL
Intervention: AS (Nab-paclitaxel plus S-1)
Number of subjects: 97
Study 35983025 — intervention group
Group type: COMPARATOR
Intervention: SOX (not explicitly defined in the abstract)
Number of subjects: 97
Study 35983090 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (TBCB)
Number of subjects: 216
Study 35983177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerene Cryotherapy Device treatment
Number of subjects: 242
Study 35983269 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial moderate or severe acute illness
Number of subjects: 289
Study 35983269 — intervention group
Group type: COMPARATOR
Intervention: Initial mild acute illness
Number of subjects: 289
Study 35983269 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 289
Study 35983331 — intervention group
Group type: EXPERIMENTAL
Intervention: mNGS-guided treatment
Number of subjects: 342
Study 35983331 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (guided by CMT)
Number of subjects: 342
Study 35983405 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly ECG screening for atrial fibrillation
Number of subjects: 0
Study 35983405 — intervention group
Group type: COMPARATOR
Intervention: Annual ECG screening for atrial fibrillation
Number of subjects: 0
Study 35983606 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group intervention for parents (two sessions, one week apart, via videoconferencing)
Number of subjects: 32
Study 35984091 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (n = 88; 31%)
Number of subjects: 282
Study 35984091 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (control group)
Number of subjects: 282
Study 35984529 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic evaluation
Number of subjects: 30
Study 35984529 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 30
Study 35984611 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-like effect (HLE) defined as ≥ 20% difference in paired gb/h-SONOCLOT™ traces for activated clotting time (ACT)
Number of subjects: 90
Study 35984611 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor XIII levels
Number of subjects: 90
Study 35984611 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VII levels
Number of subjects: 90
Study 35984611 — intervention group
Group type: EXPERIMENTAL
Intervention: gbACT > 252 s
Number of subjects: 90
Study 35984611 — intervention group
Group type: EXPERIMENTAL
Intervention: hACT > 215 s
Number of subjects: 90
Study 35984611 — intervention group
Group type: EXPERIMENTAL
Intervention: HLE > 50%
Number of subjects: 90
Study 35984611 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Factor VIII
Number of subjects: 90
Study 35984611 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Factor VII
Number of subjects: 90
Study 35984611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysis
Number of subjects: 90
Study 35984611 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous heparinoids at baseline
Number of subjects: 90
Study 35984695 — intervention group
Group type: EXPERIMENTAL
Intervention: SCI Step Together mobile health intervention
Number of subjects: 0
Study 35984695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot testing of the app by three end users
Number of subjects: 0
Study 35984695 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Change Wheel techniques included in the app
Number of subjects: 0
Study 35984695 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of SCI IKT Guiding Principles
Number of subjects: 0
Study 35984695 — intervention group
Group type: EXPERIMENTAL
Intervention: Future research plans
Number of subjects: 0
Study 35984700 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month multifaceted implementation strategy for a healthy lifestyle-promoting practice in PHC.
Number of subjects: 500
Study 35984996 — intervention group
Group type: EXPERIMENTAL
Intervention: sEphB4-HSA + pembrolizumab
Number of subjects: 70
Study 35985786 — intervention group
Group type: EXPERIMENTAL
Intervention: Density of non-residential destinations (NRDs) within 1 km of home address
Number of subjects: 2405
Study 35986100 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support from other family
Number of subjects: 833
Study 35986100 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol/drug use
Number of subjects: 833
Study 35986100 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking care of others
Number of subjects: 833
Study 35986258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nulligravida
Number of subjects: 22545
Study 35986258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravida/nulliparous
Number of subjects: 22545
Study 35986258 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpregnancy intervals less than 18 months
Number of subjects: 22545
Study 35986258 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor appetite/vomiting in the second trimester
Number of subjects: 22545
Study 35986258 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater wealth
Number of subjects: 22545
Study 35986258 — intervention group
Group type: EXPERIMENTAL
Intervention: Swelling of hands/face in the third trimester
Number of subjects: 22545
Study 35986258 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity greater than five
Number of subjects: 22545
Study 35986258 — intervention group
Group type: EXPERIMENTAL
Intervention: Male fetal sex
Number of subjects: 22545
Study 35986258 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased weight gain
Number of subjects: 22545
Study 35986306 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting interventions focusing on promoting parental reflective function (RF)
Number of subjects: 0
Study 35986671 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir plus rilpivirine
Number of subjects: 12
Study 35986671 — intervention group
Group type: COMPARATOR
Intervention: Daily dolutegravir-abacavir-lamivudine
Number of subjects: 12
Study 35986671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 12
Study 35986750 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-ECMO treatment
Number of subjects: 0
Study 35986750 — intervention group
Group type: COMPARATOR
Intervention: Standard advanced cardiac life support
Number of subjects: 0
Study 35986750 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-ECMO
Number of subjects: 0
Study 35986750 — intervention group
Group type: EXPERIMENTAL
Intervention: Venting strategies
Number of subjects: 0
Study 35986823 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR positivity (negative, mild, moderate, severe)
Number of subjects: 50
Study 35986823 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean C-reactive protein (CRP) values
Number of subjects: 50
Study 35986823 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean D-dimer values
Number of subjects: 50
Study 35986823 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean length of stay in the ICU
Number of subjects: 50
Study 35986823 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone dose
Number of subjects: 50
Study 35986823 — intervention group
Group type: COMPARATOR
Intervention: Presence of comorbidity
Number of subjects: 50
Study 35986824 — intervention group
Group type: EXPERIMENTAL
Intervention: p-ARDS
Number of subjects: 39
Study 35986824 — intervention group
Group type: COMPARATOR
Intervention: ep-ARDS
Number of subjects: 39
Study 35986824 — intervention group
Group type: EXPERIMENTAL
Intervention: PFT
Number of subjects: 39
Study 35986824 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation
Number of subjects: 39
Study 35986865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemopatch
Number of subjects: 0
Study 35987165 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus atezolizumab (Isa + Atezo)
Number of subjects: 107
Study 35987601 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) treatment
Number of subjects: 1317
Study 35987625 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient visits for pneumonia
Number of subjects: 0
Study 35987625 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient admissions for malaria
Number of subjects: 0
Study 35987625 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient visits for malaria in Mozambique
Number of subjects: 0
Study 35987625 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient admissions for malaria in Mozambique
Number of subjects: 0
Study 35987625 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment costs for malaria and pneumonia
Number of subjects: 0
Study 35987625 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely treatment for malaria and pneumonia
Number of subjects: 0
Study 35987700 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 2475
Study 35987700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense physical activity
Number of subjects: 2475
Study 35987700 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity classified as NVA
Number of subjects: 2475
Study 35987700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense physical activity classified as NVA
Number of subjects: 2475
Study 35987700 — intervention group
Group type: EXPERIMENTAL
Intervention: Total physical activity classified as EVA
Number of subjects: 2475
Study 35987700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense physical activity classified as EVA
Number of subjects: 2475
Study 35987700 — intervention group
Group type: COMPARATOR
Intervention: Moderate- or low-intensity physical activity
Number of subjects: 2475
Study 35987704 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation pharmacotherapy (7.2% of current smokers)
Number of subjects: 40004
Study 35987704 — intervention group
Group type: COMPARATOR
Intervention: Current smokers
Number of subjects: 40004
Study 35987704 — intervention group
Group type: COMPARATOR
Intervention: Ex-smokers
Number of subjects: 40004
Study 35987704 — intervention group
Group type: COMPARATOR
Intervention: Patients who stopped smoking 0-1 day before surgery
Number of subjects: 40004
Study 35987704 — intervention group
Group type: COMPARATOR
Intervention: Patients who stopped smoking 2-14 days before surgery
Number of subjects: 40004
Study 35987704 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 40004
Study 35987704 — intervention group
Group type: EXPERIMENTAL
Intervention: Having recent coronary artery disease
Number of subjects: 40004
Study 35987704 — intervention group
Group type: EXPERIMENTAL
Intervention: Having cancer
Number of subjects: 40004
Study 35987704 — intervention group
Group type: EXPERIMENTAL
Intervention: Undergoing major vascular surgery
Number of subjects: 40004
Study 35987704 — intervention group
Group type: EXPERIMENTAL
Intervention: Undergoing urgent/emergent surgery
Number of subjects: 40004
Study 35987704 — intervention group
Group type: EXPERIMENTAL
Intervention: Undergoing thoracic surgery
Number of subjects: 40004
Study 35987706 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial-intelligence colour overlay
Number of subjects: 40
Study 35987977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 890
Study 35987977 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lorazepam
Number of subjects: 890
Study 35987988 — intervention group
Group type: EXPERIMENTAL
Intervention: Artichoke freeze-dried extract (AWPC)
Number of subjects: 18
Study 35988541 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated humans
Number of subjects: 0
Study 35988541 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated BALB/c mice
Number of subjects: 0
Study 35988541 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-human primates
Number of subjects: 0
Study 35988545 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with obinutuzumab, acalabrutinib, and venetoclax after optional debulking with bendamustine
Number of subjects: 45
Study 35988546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat (5 mg, 20 mg, 50 mg twice daily during a 16-week dose-optimisation period followed by a 24-week fixed-dose period)
Number of subjects: 27
Study 35988546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat
Number of subjects: 27
Study 35988689 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) in individuals with NAFL
Number of subjects: 66
Study 35988689 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) in individuals with NASH
Number of subjects: 66
Study 35988689 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) across all groups
Number of subjects: 66
Study 35988689 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adipose tissue (VAT) from individuals with NASH
Number of subjects: 66
Study 35988815 — intervention group
Group type: EXPERIMENTAL
Intervention: LDN + tDCS
Number of subjects: 86
Study 35988815 — intervention group
Group type: EXPERIMENTAL
Intervention: LDN + tDCS Sham
Number of subjects: 86
Study 35988815 — intervention group
Group type: COMPARATOR
Intervention: Placebo + tDCS
Number of subjects: 86
Study 35988815 — intervention group
Group type: COMPARATOR
Intervention: Placebo + tDCS Sham
Number of subjects: 86
Study 35989352 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic thickening fraction (DTF) measured within 24 hours since the start of weaning, median DTF 28% (IQR 22-39%)
Number of subjects: 57
Study 35989352 — intervention group
Group type: EXPERIMENTAL
Intervention: RASS score
Number of subjects: 57
Study 35989352 — intervention group
Group type: EXPERIMENTAL
Intervention: Kelly-Matthay score
Number of subjects: 57
Study 35989352 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory oxygen fraction
Number of subjects: 57
Study 35989352 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial failure
Number of subjects: 57
Study 35989614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers carrying a male foetus
Number of subjects: 139
Study 35989614 — intervention group
Group type: COMPARATOR
Intervention: Mothers carrying a female foetus
Number of subjects: 139
Study 35989865 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment and treatment by primary care physicians
Number of subjects: 246
Study 35989865 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of medication nonadherence
Number of subjects: 246